Optometry Times

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#620291

United States

#310017

Health/Health

#5531

Traffic sources

Monthly visitors

Articles

Recent tariff decisions, appeals have no immediate effect on vision industry, The Vision Council reports

5 days ago | optometrytimes.com | Jordana Joy

In light of the recent US Court of International Trade (CIT) decision to permanently prohibit all tariffs imposed by President Donald Trump under the International Emergency Economic Powers Act (IEEPA), The Vision Council weighed in to access what the decision means for the vision industry.1 With the decision made on May 28, the CIT has given the federal government 10 days to implement a process to halt the collection of IEEPA-related duties, according to a news release.
CCS 2025: Preparing optometric students for patient care and myopia management

1 week ago | optometrytimes.com | Mark Bullimore |Jordana Joy

May 31, 2025By Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation. Mark Bullimore, MCOptom, PhD; Erin Tomiyama, OD, PhD; and Prethy Rao, MD, discussed the significance of myopia, emphasizing its role in uncorrectable visual impairment, particularly in the US.
CCS 2025: Taking a contemporary approach to dry eye disease with Dr Mitch Ibach

1 week ago | optometrytimes.com | Mitch Ibach |Emily Kaiser Maharjan |Jordana Joy

During his presentation titled "Rethinking Dry Eye Disease: A Contemporary Approach to a Complex Condition," Mitch Ibach, OD, FAAO, discussed the prevalence of dry eye disease, a significant ocular condition affecting approximately 18 million patients in the United States - 4 times more than those diagnosed with open-angle glaucoma. Ibach emphasized the growing patient awareness and motivation surrounding dry eye, which distinguishes it from other eye conditions like glaucoma.
Swept-source anterior segment-OCT aids in early diagnosis of childhood glaucoma

1 week ago | optometrytimes.com | Lynda Charters

May 30, 2025The investigators described the CASIA2 (Tomey Corporation) instrument, which is a new AS-OCT device with a swept-source laser wavelength of 1310 nm that can scan at a speed of 50,000 A-scan/second.
Pangaea Data and Topcon Healthcare announce strategic investment

1 week ago | optometrytimes.com | Jordana Joy

Health artificial intelligence (AI) company Pangaea Data has announced a strategic investment from Topcon Healthcare which aims to accelerate Pangaea’s efforts to address critical care gaps in eye health and systemic disease.1 These efforts include utilizing Pangaea’s clinically validated AI platform PALLUX, according to a news release.
Iolyx Therapeutics releases phase 2 results for ILYX-002 in autoimmune-associated dry eye disease

1 week ago | optometrytimes.com | Martin Harp

Iolyx Therapeutics announced top-line data from its phase 2 trial of ILYX-002 for the treatment of moderate-to-severe dry eye disease (DED) associated with systemic autoimmune or inflammatory conditions. The trial is a randomized, double-masked, and vehicle-controlled study conducted at multiple sites across Australia.
FDA approves Alcon’s Tryptyr (AR-15512) for signs and symptoms of dry eye disease

1 week ago | optometrytimes.com | Emily Kaiser Maharjan |Martin Harp

Alcon announced that the FDA has approved acoltremon ophthalmic solution 0.003%, a first-in-class transient receptor potential melastatin 8 (TRPM8) receptor agonist, for the treatment of the signs and symptoms of dry eye disease (DED). The drop, previously known as AR-15512, will be sold under the name Tryptyr.
Bridging disciplines and elevating care: A Q&A with John Gelles, OD, and Steven Greenstein, MD

1 week ago | optometrytimes.com | John Gelles |Steven Greenstein |Emily Kaiser Maharjan

May 28, 2025By In this Q&A, John D. Gelles, OD, and Steven Greenstein, MD, chat about what inspired them to launch the symposium, what makes this year’s agenda especially exciting, and why the future of refractive care depends on stronger collaboration between ODs and MDs.Since its inception in 2021, the Collaborative Care Symposium has helped eye care providers bridge the gap between optometry and ophthalmology. Cochaired by John D.
ARVO 2025: Miebo demonstrates favorable tolerability in prescription refill rates

1 week ago | optometrytimes.com | Bridgitte Shen Lee |Emily Kaiser Maharjan |Jordana Joy

May 28, 2025By Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, details the key takeaways from a poster presentation she participated in during ARVO 2025. In detailing a poster presentation given on perfluorohexyloctane (PFHO) (Miebo) on a dry eye disease treatment, Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO, highlighted 2 key takeaways from the research. The first takeaway emphasizes the study's robust methodology.
AI therapy planning support assistant launched by deepeye Medical receives CE mark

1 week ago | optometrytimes.com | Jordana Joy

German healthtech company deepeye Medical’s predictive artificial intelligence (AI) therapy planning assistant deepeye TPS (Therapy Planning Support) has received CE mark (Class IIa) from the EU Medical Device Regulation after certification by the Notified Body Kiwa Assurance.1 The assistant is designed to close the gap between real-world outcomes and trial data by reducing patient dropout via enhancing efficiency and, potentially, the effectiveness of intravitreal injection therapy planning,...